Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Calcium acetate | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium acetate. |
| Calcium glucoheptonate | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium glucoheptonate. |
| Calcium chloride | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium chloride. |
| Calcium | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium. |
| Calcium carbonate | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium carbonate. |
| Calcium citrate | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium citrate. |
| Calcium gluconate | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium gluconate. |
| Calcium Phosphate | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium Phosphate. |
| Calcium glubionate anhydrous | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium glubionate anhydrous. |
| Calcium lactate | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium lactate. |
| Calcium lactate gluconate | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium lactate gluconate. |
| Calcium pangamate | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium pangamate. |
| Calcium levulinate | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium levulinate. |
| Calcium cation | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium cation. |
| Calcium polycarbophil | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium polycarbophil. |
| Phenytoin | The serum concentration of Tacalcitol can be decreased when it is combined with Phenytoin. |
| Fosphenytoin | The serum concentration of Tacalcitol can be decreased when it is combined with Fosphenytoin. |